- Clinical Assistant Professor, Pathology - (Clinical Series Track)
Teaching medical students, pathology residents, and GI/liver fellows.
Novel biomarkers for prostate cancer progression. Pancreatic cancer treatment effects in response to chemoradiation. Rectal cancer disagnosis and stratification in response to chemoradiation.
Surgical PathologyPATH 850A (Spring 2020)
- Sun, B. (2020). Endoscopic tattooing: a risk for tumor implantation. International Journal of Colorectal Disease, 1-4. doi:https://doi.org/10.1007/s00384-019-03495-9
- Sun, B., & Bhatachryya, A. (2019). Diagnosis of Hepatoid Carcinoma of Extrahepatic Origins: Cell Markers and Pathologic Standards. Biomedical Journal of Scientific & Technical Research, 15(2), 11182-11187. doi:10.26717/BJSTR.2019.15.002666More infoBackground: Hepatoid adenocarcinoma (HAC) is a rare carcinoma showing hepatocellular differentiation but arising from extrahepatic organs. We herein have reported four HAC cases and reviewed literature to summarize the pathologic standards and biomarkers for diagnosis of HACs.Objectives and Methods: Cases diagnosed as HAC at the University of Arizona Medical Center Tucson were retrospectively reviewed. Relevant literature in the PubMed database prior to October, 2018 were reviewed and summarized.Results and conclusion: About 72% of reported HACs were originated from stomach, 9% from ovary, 7% from lung, 6% from pancreas, 2% from gallbladder or urinary bladder and rare cases from uterus, esophagus, jejunum, colon, rectum, or extrahepatic bile duct. Diagnosis of HAC can be challenging especially at the metastatic stage of disease with multiple organs’ involvement. Hepatocellular markers identify hepatocellular differentiation with variable sensitivity for the diagnosis of HACs from different origins. AFP expression was found in more than 90% of gastric, ovarian and urinary gallbladder HACs but only in 57% of pancreatic HACs. HepPar-1 was positive in 100% of pancreatic, gallbladder and urinary gallbladder HACs but only in 31% of gastric HACs. Glypican-3 is positive in almost all HACs tested except one gastric HAC. Differentiating HAC versus hepatocellular carcinoma is challenging due to the striking similarity in morphology and immunoprofile. Some tumor markers may help to make differentiation: serum tumor marker CA125 was elevated in 75% of ovarian HACs, and serum CEA was increased in 63% of gastric HACs; CK19 and CK7 were often strongly positive in HACs but rarely positive in hepatocellular carcinomas. Some newly identified markers such as bile salt export pump (BSEP) and multidrug-resistance protein 3 (MDR3) have been reported in distinguishing HAC from hepatocellular carcinoma but need to be further validated.
- Casanova, N., Gonzalez-Garay, M. L., Sun, B., Sun, X., & Garcia, J. G. (2019, May). Sarcoidosis And Coccidioidomycosis Share Common Tissue Transcriptome Expression Profiles. ATS International Conference. Dallas: American Thoracic Society.More infoIn this study we compared sarcoidosis gene expression profiles of lung and lymph node granulomas to tissues from patients with tuberculosis and coccidioidomycosis or Valley Fever (VF), a soil-dwelling fungi disease endemic in the southwest. We also aimed to compare sarcoidosis tissue gene expression to our previous gene signatures derived from peripheral blood mononuclear (PBMC). Incorporation of precise approaches like molecular biomarkers in the differential diagnosis will facilitate and expedite the diagnosis.